Orphan Drugs Continue to Proliferate in Europe - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
Orphan Drugs Continue to Proliferate in Europe

Source: Applied Clinical Trials

No less than 11 out of 81 medicines recommended for marketing authorization in 2013 by the Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency (EMA) were intended for the treatment of rare diseases. The comparable figures were 8 in 2012 and 4 in 2011, according to an EMA press release issued on 3 February.

Developers of orphan medicines are now making much better use of the support tools offered by the Agency and the European Orphan Regulation, noted Bruno Sepodes, Chair of the Committee for Orphan Medicinal Products (COMP), the EMA body responsible for recommending orphan designation of medicines for rare diseases.

“12 years after the European Orphan Regulation came into force, it is undoubtedly serving its purpose, with more and more orphan medicines reaching patients with rare diseases each year," he explained. "The joint efforts of the EMA committees, including the COMP, the Pediatric Committee and the CHMP, in providing scientific advice to companies during the development of their medicines, have been a driving force behind this success."
 
The volume of applications for orphan designation submitted to the Agency has increased by more than 22% since 2009, and the number of companies seeking protocol assistance increased from 82 requests in 2012 to 108 requests in 2013. Micro, small or medium-sized enterprises (SME) are particularly active in this area, accounting for around 40% of the applications for an orphan designation.
 
“In 2014, we will continue to review and adapt our internal procedures. This will help us to better meet the needs of patients, with whom the Committee has been working in close contact since its creation, and to keep up-to-date with the scientific knowledge on rare diseases,” Sepodes said. “Another priority will be to continue to actively contribute to scientific publications and scientific debate in our area.”

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

UPCOMING CONFERENCES

8th Annual Forum on Transparency and Aggregate Spend 2014
Washington, DC
August 18-20, 2014

eSource Data in Clinical Investigations
Philadelphia, PA
August 20-21, 2014

Pharmacovigilance 2014
Philadelphia, PA
September 10-11, 2014

Collaborative Research Summit
Philadelphia, PA
October 15-16, 2014

See All Conferences >>

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
87%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
8%
View Results
Untitled Document
Source: Applied Clinical Trials,
Click here